A failed Phase 3 trial does not always mean a drug is ineffective. Luca Pani of NetraMark argues that AI-driven patient selection could transform how clinical evidence is generated and interpreted.
AbbVie is betting on a multimodal approach in lung cancer by combining bispecific antibodies with antibody-drug conjugates, aiming to overcome resistance and improve patient outcomes as new clinical data emerges.
Lōkahi Therapeutics is strengthening its collaboration with The University of Alabama’s Culverhouse College of Business, giving students direct experience in evaluating real biopharma assets through the ai² Pipeline division.
Artificial intelligence has crossed a threshold in biotechnology by designing functional viruses that target bacteria, opening vast opportunities and urgent responsibilities for India and the world.
Bristol Myers Squibb has stopped work on ORM-6151, a degrader-antibody conjugate from Orum Therapeutics, after reviewing Phase I trial data.
Stanford researchers built a virtual biotech company powered by 37,000 AI agents, which quickly identified promising drug targets and independently suggested a cancer therapy later validated by a major pharmaceutical company.
Mayo Clinic researchers have shown that drugs used for advanced thyroid cancer can make aggressive tumors visible again to CAR-T cells, improving tumor control and survival in preclinical studies.
Bristol Myers Squibb has stopped development of Orum Therapeutics' CD33-targeted AML drug, erasing USD 80 million in milestone payments and leaving only one approved agent in the clinical-stage DAC field.
Dualitas Therapeutics has signed a $36.5 million upfront agreement with Roche for access to its DualScreen Bispecific Discovery Engine, with total payments that could reach $1 billion.
SK Biopharmaceuticals has signed a licensing and equity agreement with 1ST Biotherapeutics, gaining exclusive global rights to a preclinical Parkinson's disease candidate with a dual-inhibition mechanism.
